Medscape is available in 5 Language Editions – Choose your Edition here.


Essential Tremor Treatment & Management

  • Author: Deborah A Burke, MD; Chief Editor: Selim R Benbadis, MD  more...
Updated: Jul 08, 2016

Approach Considerations

Primidone and propranolol are the cornerstones of maintenance medical therapy for essential tremor. These medications provide good benefit, reducing tremor amplitude in approximately 50-70% of patients.[4, 5, 6]

Some patients require only intermittent tremor reduction, such as when attending a meeting or engaging in a social activity. For these patients, a cocktail or beer prior to the activity may be sufficient. An alternative is propranolol (10-40 mg) approximately one half hour prior to the event. Alcohol consumption is not an appropriate maintenance therapy for patients who seek tremor reduction throughout the day.[7]


For patients with disabling, medically refractory upper extremity tremor, surgery is considered. Stereotactic thalamotomy and thalamic ventralis intermedius nucleus deep brain stimulation are the procedures of choice. Both procedures offer high rates of tremor reduction in the contralateral arm. Information suggests that they are also useful in reducing head and voice tremor.[47]

Bilateral thalamotomy is associated with a relatively high risk of dysarthria, occurring in as many as 29% of patients, and a risk of cerebral hemorrhage. The potential advantage of thalamic stimulation is that it is adjustable. If the stimulation causes an adverse effect, the rate of stimulation can be modified or discontinued.

In 1996, Benabid et al initially proposed that thalamic stimulation might be a useful procedure on the opposite side in patients who have already had a unilateral thalamotomy, in an effort to avoid the potentially serious complications of bilateral thalamotomy.[48] Thalamic stimulation now is considered the procedure of choice.


Practical Management of Pharmacologic Therapy

For patients who require daily maintenance treatment for essential tremor, a decision is made whether to start with primidone or propranolol. Usually, propranolol is started first in younger patients and primidone is started first in older individuals. Generally, propranolol carries more risk of serious adverse effects in older patients than in younger ones. Additionally, younger patients, particularly those who are in school or working, find the sedating and cognitive side effects of primidone more troublesome than older patients do.

If the patient has a relative contraindication to propranolol, such as pulmonary disease or heart block, starting with primidone is preferable.

The chosen medication, primidone or propranolol, is introduced at a low dose and increased slowly until sufficient benefit is achieved or the usual maximum dosage is reached. If no benefit is derived, the patient is completely weaned off the drug before the alternative medication is started. If a partial benefit from the first drug occurs, the second medication is added and slowly increased until sufficient benefit is achieved or the usual maximum dosage is reached. If no additional benefit occurs, the patient is weaned off the second medication.

If sufficient benefit is not achieved with primidone or propranolol, other medications are considered based on the severity of the residual tremor. A beta1-receptor antagonist can be tried if necessary; in general, however, beta1-receptor antagonists are more effective than placebo but are not as effective as beta2-receptor antagonists. (Metoprolol, a relatively selective beta1-receptor antagonist, may be useful in patients with asthma or other pulmonary conditions.)

If the tremor is mild and more of a nuisance than it is disabling, a benzodiazepine (usually clonazepam) is considered. For patients with head tremor, cervical injections of botulinum toxin may be given.


Winkler and Young first noted remarkable tremor reduction in a patient treated with propranolol for paroxysmal atrial tachycardia.[5]

In a double-blind, crossover study, propranolol at doses from 60-240 mg/day reduced tremor in 75% of patients with essential tremor. In a dose-response study, 240-320 mg/day was found to be the optimal dose range, with no additional benefits above 320 mg/day.

Average tremor reduction is 50-70%, but while some patients experience marked tremor reduction, others derive no benefit from the drug. The mechanism of action probably is related to peripheral beta2-receptor antagonism.

Once an effective maintenance dose of propranolol is achieved, switching to the long-acting preparation is considered. The long-acting formulation of propranolol has an efficacy similar to that of the standard formulation and may allow the patient to take fewer daily doses. An alternative is to use the long-acting formulation from the beginning, but this requires multiple prescriptions and is more cumbersome.

American Academy of Neurology (AAN) Practice Parameters are as follows[49] :

  • Level A (established as effective)
  • Level B (possibly effective) for head tremor


O'Brien et al initially observed that primidone, when administered to a patient with epilepsy and essential tremor, reduced tremor. In a placebo-controlled study, primidone significantly reduced tremor in otherwise untreated patients and patients treated with propranolol. Doses greater than 250 mg/day did not provide additional benefit.[50]

Primidone’s mechanism of action is unknown. Active metabolites are phenylethylmalonamide (PEMA) and phenobarbital. PEMA has no effect on tremor, and phenobarbital has only modest effect on tremor. Tremor reduction is not correlated with serum levels of primidone or phenobarbital.

Adverse effects, if any, usually occur early in the course of treatment, possibly with the first dose. Acute adverse effects are minimized by starting at a very low dose and then slowly increasing the dose. However, some patients are unable to tolerate primidone even at very low doses.

AAN Practice Parameter is as follows[49] :

  • Level A (established as effective)


Topiramate is an anticonvulsant medication that enhances gamma-aminobutyric acid (GABA) activity, carbonic anhydrase inhibition, antagonism of alpha-amino-3-hydroxy-5-methylisoxazole-4 propionic acid/kainite receptors, and blockage of voltage-dependent calcium and sodium channels.

Multiple studies indicate that tremor is reduced by an average of approximately 20% in comparison with placebo. However, clinical trials indicate a fairly substantial dropout rate of 40% because of adverse effects such as cognitive difficulty and somnolence.

AAN Practice Parameter is as follows[49] :

  • Level B (probably effective)


The mechanism of tremor reduction by alcohol is unknown. In a double-blind study, the 6-carbon alcohol methylpentynol did not have any effect on tremor. This suggests that the alcohol group of ethanol is not the element that provides antitremor activity and that the antitremor effect of ethanol is not due to sedation.

Restricted intra-arterial ethanol administration does not reduce tremor in the perfused limb. This suggests that ethanol’s effect is mediated centrally.


Additional Medications

Many other medications have been reported to be of benefit in the treatment of essential tremor. Most of the evidence, however, has come from case reports and small, open-label studies.


In a randomized, double-blind, crossover study, tremor was reduced significantly by clozapine in 13 of 15 patients with drug-resistant essential tremor. The investigators compared a single 12.5 mg dose of clozapine with placebo.

A significant reduction of tremor was reported with long-term (open-label) clozapine therapy (39.9 mg/day). No tolerance was observed over 15 months.

AAN Practice Parameter is as follows[49] :

  • Level C (possibly effective) “only for refractory cases of limb tremor in ET due to the risk of agranulocytosis”


In a small, open-label case series, mirtazapine was reported to reduce tremor in patients with essential tremor and Parkinson disease.

AAN Practice Parameter is as follows[49] :

  • Level C (possibly ineffective); weak evidence suggests this treatment is ineffective


A double-blind, crossover trial comparing gabapentin (400 mg tid) with propranolol (40 mg tid) found that both drugs demonstrated significant and comparable reductions in tremor compared with baseline. However, a double-blind, placebo-controlled, crossover study identified no difference between gabapentin and placebo.

AAN Practice Parameter is as follows[49] :

  • Level B (probably effective)


Benzodiazepines, particularly clonazepam and alprazolam, are used commonly in the treatment of essential tremor, but their effectiveness is limited. They probably work to reduce the anxiety that can amplify tremor amplitude.

AAN Practice Parameters are as follows[49] :

  • Alprazolam - Level B (probably effective); "recommended with caution due to abuse potential"
  • Clonazepam - Level C (possibly effective) but "should be used with caution due to abuse potential and possible withdrawal symptoms"

Botulinum toxin

Botulinum toxin has been evaluated for the treatment of essential tremor. Its use in the treatment of tremor of the upper extremities is limited because it commonly causes weakness. It is more useful in the treatment of head tremor because it often provides benefit without unwanted, troublesome weakness.

AAN Practice Parameter is as follows[49] :

  • Level C (possibly effective) for “limb tremor in medically refractory cases”


A retrospective study by Jankovic et al evaluated 60 patients who underwent thalamotomy for medically intractable tremor and found that, of those patients with essential tremor, most showed improvement in tremor and in function. In the study, 42 patients had Parkinson disease, 6 had essential tremor, 6 had cerebellar tremor, and 6 had posttraumatic tremor. Patients were observed for a mean period of 53.4 months and for as long as 13 years.

Cessation or moderate to marked improvement in contralateral tremor with improvement in function occurred in 86% of patients with Parkinson disease, 83% of patients with essential tremor, 67% of patients with cerebellar tremor, and 50% of patients with posttraumatic tremor. Fourteen of the 60 patients had a total of 18 persistent complications, including weakness in 9 patients, dysarthria in 6, contralateral ataxia in 1, blepharospasm in 1, and pulmonary embolus resulting in death in 1.

In a study by Goldman et al of thalamotomy in 8 patients with moderate to severe essential tremor, the condition in all of the patients was reduced to a mild tremor or disappeared completely. Mild persistent dysarthria was seen in 2, and a "mild verbal cognitive defect" was seen in 1.

Stereotactic thalamotomy is less expensive than deep brain stimulation, no hardware remains, and it has been demonstrated to provide long-term efficacy. Potential adverse effects include intracerebral hemorrhage, motor weakness, dystonia, speech disturbance, and memory loss.


Thalamic Deep Brain Stimulation

In a multicenter study, measures of function improved significantly in patients with essential tremor, following the administration of high-frequency, unilateral thalamic stimulation. In the study, the results of such stimulation were assessed in 29 patients with essential tremor and 24 individuals with Parkinson disease. A blinded evaluation at 3 months with patients randomized to stimulation on or stimulation off demonstrated a significant reduction in essential tremor and Parkinson disease contralateral tremor with stimulation on. However, stimulation was commonly associated with transient paresthesias. Other adverse events were mild and well tolerated.

In a study of 14 patients with essential tremor, Ondo et al reported an average 83% reduction in contralateral arm tremor following unilateral thalamic deep brain stimulation.[39]

Pahwa et al reported good results with bilateral thalamic deep brain stimulation in 9 patients with essential tremor. Patients experienced 68% improvement in hand tremor following the first surgery and 75% improvement in the opposite hand following the second surgery. Complications were noted in 5 patients and included asymptomatic intracranial hematoma (1 patient), postoperative seizures (1 patient), hematoma over the implanted pulse generator (1 patient), lead repositioning (1 patient), and implantable pulse generator (IPG) malfunction (1 patient). Adverse effects related to stimulation were mild and resolved with the adjustment of stimulation parameters.

Two deep brain stimulation devices are approved by the FDA to reduce the symptoms of Parkinson disease and essential tremor. The first was approved in 1997 and the second in 2015.[58]


Thalamotomy Versus Deep Brain Stimulation

In a retrospective comparison study of deep brain stimulation and thalamotomy in essential tremor and Parkinson disease, Tasker demonstrated complete contralateral tremor abolition in 42% of patients treated with either procedure, near abolition in 69% of the thalamotomy group and 79% of the deep brain stimulation group, and recurrence in 15% of the deep brain stimulation group and 5% of the thalamotomy group. None of the deep brain stimulation implants and 15% of the thalamotomies had to be repeated.

In the study, adverse effects, including ataxia, dysarthria, and gait disturbance, were more common with thalamotomy (42%) than with deep brain stimulation (26%); adverse effects were persistent in 31% of people undergoing thalamotomy; and those occurring after deep brain stimulation were almost always controlled by adjusting stimulation parameters. Paresthesias were persistent in 19% of patients undergoing thalamotomy and were avoidable in deep brain stimulation by stimulation modification.

Taha et al evaluated thalamic deep brain stimulation contralateral to thalamotomy in 23 patients (6 with Parkinson disease, 15 with essential tremor, and 2 with multiple sclerosis); of 20 patients with bilateral limb tremor, 85% improved to having no tremor or only stress-induced tremor.

In a prospective study, Schuurman et al concluded that, although thalamotomy and thalamic stimulation are equally effective for tremor suppression, stimulation results in greater functional improvement and has fewer adverse effects. In the study, the investigators compared thalamic stimulation and thalamotomy in a prospective, randomized study of 68 patients with Parkinson disease, essential tremor, or multiple sclerosis.

The investigators found that functional status improved more in the thalamic stimulation group. Tremor was suppressed completely or almost completely in 30 of 33 patients who underwent thalamic stimulation, compared with 27 of 34 patients in the thalamotomy group. One patient in the stimulation group died perioperatively after an intracerebral hemorrhage.

In a long-term study of a series of patients who underwent thalamic stimulation, the rates of stimulator reoperations, explants, and device failures were relatively high, suggesting that long-term evaluations may be necessary to assess definitively the relative benefits and complications of these procedures.

Another study found gamma knife thalamotomy to be safe and effective in patients who were not eligible for open surgical techniques and had medically refractory tremor.

The main advantage of thalamic deep brain stimulation is that it is adjustable; adverse effects from stimulation can be controlled by reducing stimulation. Disadvantages of deep brain stimulation include expense, the use of a foreign body implant, the need to optimize parameters, and hardware maintenance, including battery replacement after several years.[47]



Essential tremor is slowly progressive; therefore, medication doses may need to be adjusted over time. Additionally, loss of medication benefit and long-term adverse effects are not uncommon. Adverse effects, including depression and male impotence, should be monitored in patients on propranolol.

Ongoing attention to activities of daily living, as well as to social and psychological adaptation, is warranted. The frequency of follow-up must be individualized.

Essential tremor is often familial; follow-up with family members may be appropriate. Concerns about disability arising in family members may need to be addressed.

Contributor Information and Disclosures

Deborah A Burke, MD Clinician, Sub-Investigator, Movement Disorder/Parkinson's Disease Center, University of South Florida College of Medicine; Investigator, Physician, Roskamp Institute Memory Clinic

Deborah A Burke, MD is a member of the following medical societies: American Academy of Neurology, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.


Robert A Hauser, MD, MBA Professor of Neurology, Molecular Pharmacology and Physiology, Director, USF Parkinson's Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Byrd Institute, Clinical Chair, Signature Interdisciplinary Program in Neuroscience, University of South Florida College of Medicine

Robert A Hauser, MD, MBA is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Neuroimaging, International Parkinson and Movement Disorder Society

Disclosure: Received consulting fee from Cerecor for consulting; Received consulting fee from L&M Healthcare for consulting; Received consulting fee from Cleveland Clinic for consulting; Received consulting fee from Heptares for consulting; Received consulting fee from Gerrson Lehrman Group for consulting; Received consulting fee from Indus for consulting; Received consulting fee from University of Houston for consulting; Received consulting fee from AbbVie for consulting; Received consulting fee from Adama.

Theresa A McClain, RN, MSN, ARNP-BC Advanced Registered Nurse Practitioner and Investigator, Parkinson’s Disease and Movement Disorders Center, University of South Florida College of Medicine

Theresa A McClain, RN, MSN, ARNP-BC is a member of the following medical societies: Sigma Theta Tau International

Disclosure: Received consulting fee from Teva for consulting; Received consulting fee from Schering Plough for consulting; Received consulting fee from Biotie for consulting; Received consulting fee from Novartis for consulting.

Chief Editor

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cyberonics; Eisai; Lundbeck; Sunovion; UCB; Upsher-Smith<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cyberonics; Eisai; Glaxo Smith Kline; Lundbeck; Sunovion; UCB<br/>Received research grant from: Cyberonics; Lundbeck; Sepracor; Sunovion; UCB; Upsher-Smith.


Nestor Galvez-Jimenez, MD, MSc, MHA Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, and Movement Disorders Society

Disclosure: Nothing to disclose.

Daniel H Jacobs MD, FAAN, Associate Professor of Neurology, University of Florida College of Medicine; Director for Stroke Services, Orlando Regional Medical Center

Daniel H Jacobs is a member of the following medical societies: American Academy of Neurology, American Society of Neurorehabilitation, and Society for Neuroscience

Disclosure: Teva Pharmaceutical Grant/research funds Consulting; Biogen Idex Grant/research funds Independent contractor; Serono EMD Royalty Speaking and teaching; Pfizer Royalty Speaking and teaching; Berlex Royalty Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Cuberas-Borrós G, Lorenzo-Bosquet C, Aguadé-Bruix S, et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. Clin Nucl Med. 2011 Nov. 36(11):991-6. [Medline].

  2. Antonini A, Berto P, Lopatriello S, Tamma F, Annemans L, Chambers M. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord. 2008 Nov 15. 23(15):2202-9. [Medline].

  3. Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007 Dec. 22(16):2346-51. [Medline].

  4. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology. 1989 Dec. 39(12):1587-8. [Medline].

  5. Winkler GF, Young RR. Efficacy of chronic propranolol therapy in action tremors of the familial, senile or essential varieties. N Engl J Med. 1974 May 2. 290(18):984-8. [Medline].

  6. Teräväinen H, Fogelholm R, Larsen A. Effect of propranolol on essential tremor. Neurology. 1976 Jan. 26(1):27-30. [Medline].

  7. Louis ED. Treatment of Essential Tremor: Are there Issues We are Overlooking?. Front Neurol. 2011. 2:91. [Medline]. [Full Text].

  8. Walter AR, Bower JH, Ahlskog JE et al. Increased risk of essential tremor in first-degree relative of patients with Parkinson’s disease. Mov Disord. Aug 15 2007. 22(11):

  9. Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. Mov Disord. 2008 Jan 30. 23(2):174-82. [Medline].

  10. Shill HA, Adler CH, Sabbagh MN, et al. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology. 2008 Apr 15. 70(16 Pt 2):1452-5. [Medline].

  11. Louis ED, Zheng W, Mao X, Shungu DC. Blood harmane is correlated with cerebellar metabolism in essential tremor: a pilot study. Neurology. 2007 Aug 7. 69(6):515-20. [Medline].

  12. Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol. 2005 Jun. 62(6):1004-7. [Medline].

  13. Louis ED, Vonsattel JP, Honig LS, Ross GW, Lyons KE, Pahwa R. Neuropathologic findings in essential tremor. Neurology. 2006 Jun 13. 66(11):1756-9. [Medline].

  14. Shin DH, Han BS, Kim HS, Lee PH. Diffusion tensor imaging in patients with essential tremor. AJNR Am J Neuroradiol. 2008 Jan. 29(1):151-3. [Medline].

  15. Bermejo-Pareja F, Louis ED, Benito-Leon J. Risk of incident dementia in essential tremor: a population-based study. Mov Disord. 2007 Aug 15. 22(11):1573-80. [Medline].

  16. Benito-Leon J, Louis ED, Bermejo-Pareja F. Elderly-onset essential tremor is associated with dementia. Neurology. 2006 May 23. 66(10):1500-5. [Medline].

  17. Klebe S, Stolze H, Grensing K, Volkmann J, Wenzelburger R, Deuschl G. Influence of alcohol on gait in patients with essential tremor. Neurology. 2005 Jul 12. 65(1):96-101. [Medline].

  18. Daniels C, Peller M, Wolff S, et al. Voxel-based morphometry shows no decreases in cerebellar gray matter volume in essential tremor. Neurology. 2006 Oct 24. 67(8):1452-6. [Medline].

  19. Ross GW, Dickson D, Cersosimo M. Pathological investigation of essential tremor. Neurology. Apr 2004. 62(7) S5:A537-A538.

  20. Ma S, Davis TL, Blair MA, et al. Familial essential tremor with apparent autosomal dominant inheritance: should we also consider other inheritance modes?. Mov Disord. 2006 Sep. 21(9):1368-74. [Medline].

  21. Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007 Jun. 130:1456-64. [Medline].

  22. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord. 1997 Nov. 12(6):859-64. [Medline].

  23. Shatunov A, Sambuughin N, Jankovic J, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006 Sep. 129:2318-31. [Medline].

  24. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005 Feb 8. 64(3):417-21. [Medline].

  25. Thier S, Lorenz D, Nothnagel M, et al. LINGO1 polymorphisms are associated with essential tremor in Europeans. Mov Disord. 2010 Apr 30. 25(6):717-23. [Medline].

  26. Clark LN, Park N, Kisselev S, Rios E, Lee JH, Louis ED. Replication of the LINGO1 gene association with essential tremor in a North American population. Eur J Hum Genet. 2010 Jul. 18(7):838-43. [Medline]. [Full Text].

  27. Tan EK, Teo YY, Prakash KM, et al. LINGO1 variant increases risk of familial essential tremor. Neurology. 2009 Oct 6. 73(14):1161-2. [Medline]. [Full Text].

  28. Dogu O, Sevim S, Camdeviren H, et al. Prevalence of essential tremor: door-to-door neurologic exams in Mersin Province, Turkey. Neurology. 2003 Dec 23. 61(12):1804-6. [Medline].

  29. Louis ED, Barnes LF, Ford B, Pullman SL, Yu Q. Ethnic differences in essential tremor. Arch Neurol. 2000 May. 57(5):723-7. [Medline].

  30. Tan EK, Lum SY, Prakash KM. Clinical features of childhood onset essential tremor. Eur J Neurol. 2006 Dec. 13(12):1302-5. [Medline].

  31. Louis ED, Dogu O. Does age of onset in essential tremor have a bimodal distribution? Data from a tertiary referral setting and a population-based study. Neuroepidemiology. 2007. 29(3-4):208-12. [Medline].

  32. Louis ED, Ottman R. Study of possible factors associated with age of onset in essential tremor. Mov Disord. 2006 Nov. 21(11):1980-6. [Medline].

  33. Louis ED, Benito-Leon J, Ottman R, Bermejo-Pareja F. A population-based study of mortality in essential tremor. Neurology. 2007 Nov 20. 69(21):1982-9. [Medline].

  34. Rajput A, Robinson CA, Rajput AH. Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology. 2004 Mar 23. 62(6):932-6. [Medline].

  35. Thawani SP, Schupf N, Louis ED. Essential tremor is associated with dementia: prospective population-based study in New York. Neurology. 2009 Aug 25. 73(8):621-5. [Medline]. [Full Text].

  36. Chatterjee A, Jurewicz EC, Applegate LM, Louis ED. Personality in essential tremor: further evidence of non-motor manifestations of the disease. J Neurol Neurosurg Psychiatry. 2004 Jul. 75(7):958-61. [Medline].

  37. Miller KM, Okun MS, Fernandez HF, Jacobson CE 4th, Rodriguez RL, Bowers D. Depression symptoms in movement disorders: comparing Parkinson's disease, dystonia, and essential tremor. Mov Disord. 2007 Apr 15. 22(5):666-72. [Medline].

  38. Benito-Leon J, Louis ED, Bermejo-Pareja F. Reported hearing impairment in essential tremor: a population-based case-control study. Neuroepidemiology. 2007. 29(3-4):213-7. [Medline].

  39. Ondo W, Jankovic J, Schwartz K, Almaguer M, Simpson RK. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998 Oct. 51(4):1063-9. [Medline].

  40. Stolze H, Petersen G, Raethjen J, Wenzelburger R, Deuschl G. The gait disorder of advanced essential tremor. Brain. 2001 Nov. 124:2278-86. [Medline].

  41. Deeb J. Gannon K. Shah M, et al. Comparison of datscan imaging and smell testing in essential tremor and Parkinson disease. Jr Neurol, Neurosurg. & Psych. Sept 2007. 78(9):1018-1019.

  42. Findley LJ, Shah M. Muhammed N, et al. Olfactory tests distinguish essential from parkinsonian tremor. Evidence of enhanced detection and age resistance in familial essential tremor. J Neurol Neurosurg Psych. Jan 2006. 77(1):140.

  43. Doep F. Plotkin M, Siegel L. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson’s disease and essential tremor. Mov. Disord. Dec 7 1007. 23(3):(405-410).

  44. Stockner H, Sojer M, K KS, et al. Midbrain sonography in patients with essential tremor. Mov Disord. 2007 Feb 15. 22(3):414-7. [Medline].

  45. Luo WF, Zhang YC, Sheng YJ, Fang JC, Liu CF. Transcranial sonography on Parkinson's disease and essential tremor in a Chinese population. Neurol Sci. 2011 Dec 11. [Medline].

  46. Kim JS, Oh YS, Kim YI, Koo JS, Yang DW, Lee KS. Transcranial sonography (TCS) in Parkinson's disease (PD) and essential tremor (ET) in relation with putative premotor symptoms of PD. Arch Gerontol Geriatr. 2012 Jan 23. [Medline].

  47. Fytagoridis A, Sandvik U, Aström M, Bergenheim T, Blomstedt P. Long term follow-up of deep brain stimulation of the caudal zona incerta for essential tremor. J Neurol Neurosurg Psychiatry. 2011 Dec 28. [Medline].

  48. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg. 1996 Feb. 84(2):203-14. [Medline].

  49. [Guideline] Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 2011 Nov 8. 77(19):1752-5. [Medline]. [Full Text].

  50. O'Brien MD, Upton AR, Toseland PA. Benign familial tremor treated with primidone. Br Med J (Clin Res Ed). 1981 Jan 17. 282(6259):178-80. [Medline]. [Full Text].

  51. Elias WJ, Huss D, Voss T, Loomba J, Khaled M, Zadicario E, et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013 Aug 15. 369(7):640-8. [Medline].

  52. Goldman MS, Ahlskog JE, Kelly PJ. The symptomatic and functional outcome of stereotactic thalamotomy for medically intractable essential tremor. J Neurosurg. 1992 Jun. 76(6):924-8. [Medline].

  53. Kondziolka D, Ong JG, Lee JY, Moore RY, Flickinger JC, Lunsford LD. Gamma Knife thalamotomy for essential tremor. J Neurosurg. 2008 Jan. 108(1):111-7. [Medline].

  54. Pahwa R, Lyons KL, Wilkinson SB, et al. Bilateral thalamic stimulation for the treatment of essential tremor. Neurology. 1999 Oct 22. 53(7):1447-50. [Medline].

  55. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med. 2000 Feb 17. 342(7):461-8. [Medline].

  56. Taha JM, Janszen MA, Favre J. Thalamic deep brain stimulation for the treatment of head, voice, and bilateral limb tremor. J Neurosurg. 1999 Jul. 91(1):68-72. [Medline].

  57. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol. 1998 Feb. 49(2):145-53; discussion 153-4. [Medline].

  58. Jeffrey, S. FDA Okays Brio Neurostimulation System for PD, ET. Medscape Medical News. Available at June 12, 2015; Accessed: June 17, 2015.

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.